| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 441 | 2021 |
| Immunologic treatments for precancerous lesions and uterine cervical cancer P Vici, L Mariani, L Pizzuti, D Sergi, L Di Lauro, E Vizza, F Tomao, ... Journal of Experimental & Clinical Cancer Research 33, 1-15, 2014 | 220 | 2014 |
| The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review SM Swain, P Vici Journal of cancer research and clinical oncology 130, 1-7, 2004 | 196 | 2004 |
| Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. M Lopez, P Vici, K Di Lauro, F Conti, G Paoletti, A Ferraironi, R Sciuto, ... Journal of Clinical Oncology 16 (1), 86-92, 1998 | 185 | 1998 |
| Triple-negative breast cancer: new perspectives for targeted therapies F Tomao, A Papa, E Zaccarelli, L Rossi, D Caruso, M Minozzi, P Vici, ... OncoTargets and therapy, 177-193, 2015 | 168 | 2015 |
| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 157 | 2020 |
| Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in … V Graziano, A Grassadonia, L Iezzi, P Vici, L Pizzuti, M Barba, A Quinzii, ... The Breast 44, 33-38, 2019 | 155 | 2019 |
| Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 147 | 2015 |
| Bevacizumab in ovarian cancer: A critical review of phase III studies L Rossi, M Verrico, E Zaccarelli, A Papa, M Colonna, M Strudel, P Vici, ... Oncotarget 8 (7), 12389, 2017 | 119 | 2017 |
| Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide P Papaldo, M Lopez, P Marolla, E Cortesi, M Antimi, E Terzoli, P Vici, ... Journal of clinical oncology 23 (28), 6908-6918, 2005 | 118 | 2005 |
| Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019 | 109 | 2019 |
| Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, ... Expert review of vaccines 15 (10), 1327-1336, 2016 | 106 | 2016 |
| Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach F Tomao, A Papa, L Rossi, M Strudel, P Vici, G Lo Russo, S Tomao Journal of Experimental & Clinical Cancer Research 32, 1-14, 2013 | 103 | 2013 |
| Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma CL Maini, A Tofani, R Sciuto, A Semprebene, R Cavaliere, M Mottolese, ... Journal of Nuclear Medicine 38 (10), 1546-1551, 1997 | 98 | 1997 |
| The sexist behaviour of immune checkpoint inhibitors in cancer therapy? A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ... Oncotarget 8 (59), 99336, 2017 | 92 | 2017 |
| Prognostic value of 99mTc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy R Sciuto, R Pasqualoni, S Bergomi, G Petrilli, P Vici, F Belli, C Botti, ... Journal of Nuclear Medicine 43 (6), 745-751, 2002 | 89 | 2002 |
| The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications M Maugeri-Saccà, M Barba, L Pizzuti, P Vici, L Di Lauro, R Dattilo, I Vitale, ... Expert reviews in molecular medicine 17, e14, 2015 | 88 | 2015 |
| Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical … A Grassadonia, I Sperduti, P Vici, L Iezzi, D Brocco, T Gamucci, L Pizzuti, ... Journal of Clinical Medicine 7 (12), 542, 2018 | 87 | 2018 |
| Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review L Mariani, P Vici, B Suligoi, G Checcucci-Lisi, R Drury Advances in therapy 32, 10-30, 2015 | 87 | 2015 |
| Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and … P Papaldo, M Lopez, E Cortesi, E Cammilluzzi, M Antimi, E Terzoli, ... Journal of clinical oncology 21 (18), 3462-3468, 2003 | 81 | 2003 |
